Added to YB: 2025-03-17
Pitch date: 2025-03-14
STOK [bullish]
Stoke Therapeutics, Inc.
+276.63%
current return
Author Info
Vulpes’s Substack - B.S/PhD in Biology. Former analyst at biotech-specialist hedge fund. Citizen of Graham and Doddsville. Boston, MA. Sign up for the newsletter.
Company Info
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression.
Market Cap
$1.5B
Pitch Price
$8.60
Price Target
N/A
Dividend
N/A
EV/EBITDA
38.17
P/E
38.72
EV/Sales
5.79
Sector
Biotechnology
Category
growth
Stoke Therapeutics, Inc. - $STOK
STOK: Zorevunersen for Dravet Syndrome, high PoS, possibly best-in-class. Undervalued due to catalyst desert until 2027 Ph3 data, Biogen deal disappointment. Ph1/2 data promising: >50% seizure reduction, cognitive improvements. Biogen deal funds through 2028. $500M market cap vs potential $1B+ peak sales. High PoS, PRV potential.
Read full article (6 min)